2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 1
1
Status
Terminated
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Lymphoid
2
Dermatologic
2
Conditions
Neoplasms
2
Mycosis Fungoides
2
Lymphoproliferative Disorders
2
Lymphoma, T-Cell, Cutaneous
2
Lymphoma, T-Cell
2
Lymphoma, Non-Hodgkin
2
Lymphoma
2
Lymphatic Diseases
2
Immunoproliferative Disorders
2
Immune System Diseases
2
Interventions
Cisplatin
1514
Carboplatin
1416
Cyclophosphamide
1359
Gemcitabine
1235
Bevacizumab
1223
Paclitaxel
1210
Radiotherapy
1173
Docetaxel
1079
pembrolizumab
1026
Oxaliplatin
934
Capecitabine
898
Fluorouracil
832
Rituximab
729
Doxorubicin
683
Nivolumab
679
Dexamethasone
665
Etoposide
660
Irinotecan
622
Leucovorin
574
Pemetrexed
508
Drug Therapy
491
Cetuximab
481
Trastuzumab
467
Cytarabine
466
Magnetic Resonance Spectroscopy
457
Filgrastim
446
Prednisone
432
Lenalidomide
409
Specimen Handling
407
Temozolomide
400
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 2
×
cobomarsen
×
Clear all
NCT03713320
2022-04-08
SOLAR
miRagen Therapeutics, Inc.
Phase 2
Terminated
37 enrolled
23 charts
NCT03837457
2020-11-19
PRISM
miRagen Therapeutics, Inc.
Phase 2
Terminated
8 enrolled